Insider Buys
This tool is in beta, validation in progress.
Score components and checks ✓/✗ are not accurate for every transaction yet.
Score components and checks ✓/✗ are not accurate for every transaction yet.
Risk Factors Update Summary
- Our commercialization and collaborative arrangements may lead to disputes affecting product success. This could delay recovery of development costs.
- The terms of our $500 million financing agreement could limit operational flexibility and growth opportunities. Failure to comply may accelerate debt repayment.
- If market opportunities for our approved candidates are smaller than expected, it could adversely affect our financial condition and results of operations.
- We expect to rely on Vanscoy Rare Pharmacy for a significant portion of plozasiran sales. Their financial failure could adversely affect our revenues.
- Our internal manufacturing capabilities are limited, and we may depend on third-party manufacturers for clinical trials and future commercialization.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=879407&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.